FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376149600> ?p ?o ?g. }

• W4376149600 abstract "Abstract Background c -KIT mutations are found in approximately 15% of the patients with malignant melanoma; agents such as imatinib have previously shown high response rates. Regorafenib, an oral multikinase inhibitor, acts against wild-type and mutant KIT. This multi-institutional phase II single-arm study aimed to evaluate the efficacy of regorafenib against metastatic malignant melanoma harboring the c- KIT mutation. Methods Patients with recurrent/metastatic melanoma positive for c- KIT mutations, whose disease progressed after at least one line of systemic treatment, were eligible. The patients received oral regorafenib 160 mg once daily for 3 weeks (4-week cycle). The primary endpoint was the disease control rate (DCR), and the secondary endpoints were safety, overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results In all, 153 patients were screened for c- KIT mutations and 23 patients were enrolled (December 2014–January 2022). c- KIT mutations were frequently reported in exon 11 (14/23, 60.9%), followed by exons 13, 17, and 9 in 5 (21.7%), 5 (21.7%), and 2 (8.7%) patients, respectively. The DCR at 8 weeks was 73.9%, with 2 patients (8.7%) achieving CR, 5 (21.7%) achieving PR, and 10 (43.5%) showing stable disease. The ORR was 30.4% (7/23). The median follow-up period was 15.2 months (95% confidence interval [CI], 10.0–21.5), and median OS and PFS were 21.5 months (95% CI, 15.1–27.9) and 7.1 months (95% CI, 5.0–9.2), respectively. Circulating tumor DNA (ctDNA) analysis in selected patients showed high c- KIT correlation (85.7%) with tissue-based tumor mutational profiles. Skin reactions, including Palmar-plantar erythrodysesthesia (52.2%) and skin rash (30.4%) were the most common adverse events (AEs). Grade 3 AEs, including infection, rash, mucositis, and marrow suppression, occurred in 9 patients (39.1%). Conclusion Regorafenib in second- or later-line settings demonstrated significant activity in patients with metastatic melanoma harboring c- KIT mutations, with an ORR of 30.4% and DCR of 73.9%. Trial registration ClinicalTrials.gov NCT02501551, registered Jul 17, 2015." @default.
• W4376149600 created "2023-05-12" @default.
• W4376149600 creator A5017973140 @default.
• W4376149600 creator A5022738306 @default.
• W4376149600 creator A5023718619 @default.
• W4376149600 creator A5038084115 @default.
• W4376149600 creator A5043025424 @default.
• W4376149600 creator A5061987787 @default.
• W4376149600 creator A5071809047 @default.
• W4376149600 creator A5084818663 @default.
• W4376149600 creator A5088383868 @default.
• W4376149600 date "2023-05-11" @default.
• W4376149600 modified "2023-09-26" @default.
• W4376149600 title "A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)" @default.
• W4376149600 cites W1917632054 @default.
• W4376149600 cites W1941813713 @default.
• W4376149600 cites W1968209756 @default.
• W4376149600 cites W1977607284 @default.
• W4376149600 cites W2001719099 @default.
• W4376149600 cites W2013950475 @default.
• W4376149600 cites W2019607817 @default.
• W4376149600 cites W2027735722 @default.
• W4376149600 cites W2096223992 @default.
• W4376149600 cites W2097409998 @default.
• W4376149600 cites W2103152130 @default.
• W4376149600 cites W2103549763 @default.
• W4376149600 cites W2112121482 @default.
• W4376149600 cites W2116922255 @default.
• W4376149600 cites W2147474070 @default.
• W4376149600 cites W2147834058 @default.
• W4376149600 cites W2152897456 @default.
• W4376149600 cites W2560499218 @default.
• W4376149600 cites W2607491338 @default.
• W4376149600 cites W2740512285 @default.
• W4376149600 cites W2769575972 @default.
• W4376149600 cites W2801649412 @default.
• W4376149600 cites W2806413494 @default.
• W4376149600 cites W2916625421 @default.
• W4376149600 cites W3039385984 @default.
• W4376149600 cites W3097816349 @default.
• W4376149600 cites W3131556132 @default.
• W4376149600 cites W3133611739 @default.
• W4376149600 cites W3185217000 @default.
• W4376149600 cites W4210978762 @default.
• W4376149600 cites W4281679396 @default.
• W4376149600 doi "https://doi.org/10.21203/rs.3.rs-2906574/v1" @default.
• W4376149600 hasPublicationYear "2023" @default.
• W4376149600 type Work @default.
• W4376149600 citedByCount "0" @default.
• W4376149600 crossrefType "posted-content" @default.
• W4376149600 hasAuthorship W4376149600A5017973140 @default.
• W4376149600 hasAuthorship W4376149600A5022738306 @default.
• W4376149600 hasAuthorship W4376149600A5023718619 @default.
• W4376149600 hasAuthorship W4376149600A5038084115 @default.
• W4376149600 hasAuthorship W4376149600A5043025424 @default.
• W4376149600 hasAuthorship W4376149600A5061987787 @default.
• W4376149600 hasAuthorship W4376149600A5071809047 @default.
• W4376149600 hasAuthorship W4376149600A5084818663 @default.
• W4376149600 hasAuthorship W4376149600A5088383868 @default.
• W4376149600 hasBestOaLocation W43761496001 @default.
• W4376149600 hasConcept C121608353 @default.
• W4376149600 hasConcept C126322002 @default.
• W4376149600 hasConcept C143998085 @default.
• W4376149600 hasConcept C197934379 @default.
• W4376149600 hasConcept C203092338 @default.
• W4376149600 hasConcept C2776248978 @default.
• W4376149600 hasConcept C2777658100 @default.
• W4376149600 hasConcept C2778822529 @default.
• W4376149600 hasConcept C2779134260 @default.
• W4376149600 hasConcept C31760486 @default.
• W4376149600 hasConcept C44249647 @default.
• W4376149600 hasConcept C502942594 @default.
• W4376149600 hasConcept C526805850 @default.
• W4376149600 hasConcept C535046627 @default.
• W4376149600 hasConcept C71924100 @default.
• W4376149600 hasConcept C90924648 @default.
• W4376149600 hasConceptScore W4376149600C121608353 @default.
• W4376149600 hasConceptScore W4376149600C126322002 @default.
• W4376149600 hasConceptScore W4376149600C143998085 @default.
• W4376149600 hasConceptScore W4376149600C197934379 @default.
• W4376149600 hasConceptScore W4376149600C203092338 @default.
• W4376149600 hasConceptScore W4376149600C2776248978 @default.
• W4376149600 hasConceptScore W4376149600C2777658100 @default.
• W4376149600 hasConceptScore W4376149600C2778822529 @default.
• W4376149600 hasConceptScore W4376149600C2779134260 @default.
• W4376149600 hasConceptScore W4376149600C31760486 @default.
• W4376149600 hasConceptScore W4376149600C44249647 @default.
• W4376149600 hasConceptScore W4376149600C502942594 @default.
• W4376149600 hasConceptScore W4376149600C526805850 @default.
• W4376149600 hasConceptScore W4376149600C535046627 @default.
• W4376149600 hasConceptScore W4376149600C71924100 @default.
• W4376149600 hasConceptScore W4376149600C90924648 @default.
• W4376149600 hasLocation W43761496001 @default.
• W4376149600 hasOpenAccess W4376149600 @default.
• W4376149600 hasPrimaryLocation W43761496001 @default.
• W4376149600 hasRelatedWork W2590127414 @default.
• W4376149600 hasRelatedWork W2590216633 @default.
• W4376149600 hasRelatedWork W2756758332 @default.
• W4376149600 hasRelatedWork W3122024015 @default.
• W4376149600 hasRelatedWork W3170112147 @default.

• next